Skip to main content

Table 1 Comparative Pathogenicity of 264.7MuLVs and Mo-MuLV in Mice

From: Expression of infectious murine leukemia viruses by RAW264.7 cells, a potential complication for studies with a widely used mouse macrophage cell line

     

Diagnosis3

Mouse Strain

Inoculum

Virus dose1

#pos/#inoc2

Latency (days)

% positive

LL-T

LL-B

Erythroid

Other

NIH Swiss

Mo-MuLV

104.4

6/6

87 +/- 16

100

4

0

24

0

  

102.2

10/10

93 +/- 13

100

10

0

0

0

 

RAW264.7 cell-free supernatant

101.0

5/7

259 +/- 68

71

3

0

1

15

  

102.5

12/15

163 +/- 68

80

5

4

3

0

 

264.7-MuLV, SC-1 passage

102.2

3/3

146 +/- 24

100

2

1

0

0

 

None

-

0/5

      

BALB/c

Mo-MuLV

104.4

5/5

98 +/- 14

100

5

0

0

0

 

RAW264.7 cell-free supernatant

101.0

2/2

255

100

1

0

1

0

  

102.5

7/12

168 +/- 53

58

4

24

1

0

 

264.7-MuLV SC-1 passage

102.2

5/5

216 +/- 84

100

4

0

0

16

 

None

-

0/4

      
  1. 1 pfu/mouse of ecotropic MuLV, based on XC plaque titration in SC-1 cells; polytropic MuLV titer not determined.
  2. 2 number of mice positive for hematopoietic disease/number inoculated.
  3. 3 LL, lymphoblastic lymphoma;, T, T-cell lineage; B, B-cell lineage; erythroid, erythroleukemia (PAX5 and CD3 negative).
  4. 4 One case also had early Thymic T-LL.
  5. 5 Mast cell tumor, spleen and bone marrow (366d post-inoculation).
  6. 6 Early splenic marginal zone lymphoma (295d post-inoculation) ; also very early T-LL in thymus.
Back to article page

Retrovirology

ISSN: 1742-4690

Contact us